The U.S. Food and Drug Administration has approved FluMist, a nasal spray flu vaccine by MedImmune LLC, for self-administration or caregiver-administration. This marks a significant development in the prevention of influenza, as FluMist becomes the first flu vaccine that does not require administration by a healthcare provider. The vaccine is approved for individuals aged 2 […]
AstraZeneca’s MedImmune and Sanofi Pasteur have formed a research and development alliance for a new infant respiratory drug, MEDI8897 which they are planning to commercialize after getting through the clinical trials and the necessary regulatory approvals.
AstraZeneca’s biotech arm, MedImmune, and Sanofi Pasteur, the vaccines division of French pharmaceutical giant Sanofi, have entered into a significant research and development collaboration. The partnership, valued at approximately €615 million, aims to advance the development of MEDI8897, a monoclonal antibody for treating respiratory syncytial virus (RSV) infections in infants and children. Strategic Collaboration to […]